Clinical Trials · NCT07150975
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals.
- Enrollment
- 420
- Start date
- Sep 2025
- Locations
- 1 site, China
- Primary endpoint
- Percentage change in body weight from baseline after 52 weeks (W) of treatment.